




RealRate

# PHARMACEUTICAL 2021

Merus N.V.  
Rank 247 of 402

# Merus





RealRate

# PHARMACEUTICAL 2021

Merus N.V.  
Rank 247 of 402

# Merus

The relative strengths and weaknesses of Merus N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merus N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Merus N.V. is the variable Other Liabilities, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 4.9% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	217,993
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,746
Liabilities, Non-Current	2,521
Other Assets	9,109
Other Compr. Net Income	7,485
Other Expenses	503
Other Liabilities	79,687
Other Net Income	-9,132
Other Revenues	29,943
Property and Equipment	4,115
Research and Development	70,040
Selling, General and Administrative Expense	35,781

Output Variable	Value in 1000 USD
Assets	231,217
Liabilities	128,954
Expenses	106,324
Revenues	29,943
Stockholders Equity	102,263
Net Income	-85,513
Comprehensive Net Income	-81,770
Economic Capital Ratio	52%